NASDAQ
8.56USD
+0.51 (+6.34%)
We have scored 13 news catalysts on Precigen, Inc. (PGEN) over the past 12 months. The biggest single-day move next to one of them came Nov 15, 2025, when PGEN closed +25.6%: “Precigen (NASDAQ:PGEN) Stock Price Up 28.9% on Analyst Upgrade”. Coverage across the window leans positive (average ticker sentiment +0.58). Most of the impact sits in sector healthcare and pricing power structural.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.1B
P/E
—
EPS
—
Beta
1.02
52W range
2.99-8.98
Day range
8.09–8.98
Open
8.13
Prev close
8.05
Volume
11.7M
Avg volume
5.2M
Dividend
0.00
IPO
2013-08-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Precigen, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PGEN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
